Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance

Neuropharmacology. 2004 Dec;47(7):1081-92. doi: 10.1016/j.neuropharm.2004.07.040.

Abstract

An essential element of the signalling cascade leading to synaptic plasticity is the intracellular second messenger molecule guanosine 3',5'-cyclic monophosphate (cGMP). Using the novel, potent, and selective inhibitor Bay 60-7550, we show that the enzyme 3',5'-cyclic nucleotide phosphodiesterase type 2 (PDE2) is responsible for the degradation of newly synthesized cGMP in cultured neurons and hippocampal slices. Inhibition of PDE2 enhanced long-term potentiation of synaptic transmission without altering basal synaptic transmission. Inhibition of PDE2 also improved the performance of rats in social and object recognition memory tasks, and reversed MK801-induced deficits in spontaneous alternation in mice in a T-maze. Our data provide strong evidence that inhibition of PDE2 can improve memory functions by enhancing neuronal plasticity.

MeSH terms

  • Animals
  • CHO Cells
  • Cattle
  • Cricetinae
  • Cyclic AMP / metabolism
  • Cyclic GMP / metabolism*
  • Exonucleases / antagonists & inhibitors*
  • Guinea Pigs
  • Hippocampus / cytology
  • Hippocampus / drug effects
  • Hippocampus / metabolism
  • Humans
  • Immunohistochemistry
  • Long-Term Potentiation / drug effects
  • Male
  • Maze Learning / drug effects
  • Memory / drug effects*
  • Mice
  • Mice, Inbred C57BL
  • Neuronal Plasticity / drug effects*
  • Neurons / drug effects
  • Neurons / metabolism*
  • Phosphodiesterase Inhibitors / pharmacology*
  • Psychomotor Performance / drug effects*
  • Rats
  • Rats, Wistar
  • Recombinant Proteins
  • Signal Transduction / drug effects

Substances

  • Phosphodiesterase Inhibitors
  • Recombinant Proteins
  • Cyclic AMP
  • Exonucleases
  • spleen exonuclease
  • Cyclic GMP